β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians

  • Daisuke YabeEmail author
  • Yutaka Seino
  • Mitsuo Fukushima
  • Susumu Seino
Open Access
Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pathogenesis of Type 2 Diabetes and Insulin Resistance


Type 2 diabetes (T2DM) is one of the most serious global health problems and is mainly a result of the drastic increase in East Asia, which includes over a fourth of the global diabetes population. Lifestyle factors and ethnicity are two determinants in the etiology of T2DM, and lifestyle changes such as higher fat intake and less physical activity link readily to T2DM in East Asians. It is widely recognized that T2DM in East Asians is characterized primarily by β cell dysfunction, which is evident immediately after ingestion of glucose or meal, and less adiposity compared to the disease in Caucasians. These pathophysiological differences have an important impact on therapeutic approaches. Here, we revisit the pathogenesis of T2DM in light of β cell dysfunction versus insulin resistance in East Asians and discuss ethnic differences in the contributions of insulin secretion and insulin resistance, together with incretin secretin and action, to glucose intolerance.


Type 2 diabetes Insulin secretion Insulin resistance East Asian Incretin 


The rapidly increasing type 2 diabetes (T2DM) worldwide is one of the most serious health problems today. The number of patients with diabetes, estimated to be 385 million in 2014, is expected to be 592 million by 2035 [1], partly due to the drastic increase of patients in East Asian countries, which now includes a fourth of the global diabetes population (Table 1). T2DM in East Asian countries are characterized by lesser obesity and younger age of onset [2, 3] It is known that lifestyle factors and ethnicity are important determinants in the etiology of T2DM [4, 5••], and it is suggested that lifestyle changes such as higher fat intake and less physical activity link more readily to T2DM development in East Asians, as first demonstrated in studies of Japanese Americans in comparison with native Japanese counterparts [6, 7•]. To prevent and better manage T2DM in East Asian countries, it is important to understand the pathophysiology of T2DM in East Asians.
Table 1

Comparison of prevalence of diabetes, proportion undiagnosed, age distribution, and related expenditure among adults aged 20–79 in East Asian countries compared to the USA


Prevalence (%)


% undiagnosed

% aged 20–39

% aged 60–79

Cost per case (USD)








United States of America














Hong Kong





















Dem. People’s Republic of Korea







Republic of Korea





















Data source [1]

Dem. Democratic, n.a. not available

T2DM in East Asians is characterized primarily by β cell dysfunction, which is evident immediately after ingestion of glucose or mixed meal, and less obesity compared to Caucasians [8•, 9•, 10]. Insulin resistance, as indicated by the homeostatic model assessment (HOMA) of insulin resistance (IR), is generally higher in Caucasians, while β cell response, as measured by HOMA of β cell function and insulinogenic index (IGI), is lower in East Asians. These pathophysiological differences in the manifestation of the disease have a crucial impact on the appropriate preventive and therapeutic approaches. In this article, we revisit the pathogenesis of T2DM with reference to β cell dysfunction versus insulin resistance, together with incretin secretion and action, in East Asians and discuss ethnic differences in the contributions of insulin secretion and insulin resistance to glucose intolerance.

Rapid Increase in T2DM and Westernized Lifestyle Changes Among East Asians

Historically, the prevalence of T2DM among East Asians was low compared with that in the United States of America (USA). Nevertheless, reports of a higher diabetes prevalence in Japanese Americans than in the general American population indicated that Japanese are not protected from diabetes. Indeed, in the early 1960s, the prevalence of diabetes in Hawaii was found to be 20.1 per 1000 person-years for Japanese and 7.3 for Caucasian [11], suggesting that Japanese might be at a special risk of developing diabetes upon exposure to lifestyles in the USA. This notion was further supported by research demonstrating higher rates of glucose intolerance among Japanese Americans living in Hawaii and Los Angeles than that in native Japanese [12]. About the same time, West found that lifestyle-related factors and obesity exert an especially strong influence on the progression of diabetes in Native Americans [13]. It is now widely accepted that obesity, through its association with insulin resistance, increases the risk of T2DM [14]. Japanese Americans, with lower body mass index (BMI) compared to other ethnic groups, develop diabetes at a rate that is more often associated with obesity in Caucasian [15]. In the late 1970s, Fujimoto et al. initiated the study of Japanese Americans in Seattle to clarify why Japanese Americans so readily develop diabetes [7•, 16]. They reported that daily calorie intake was comparable between Japanese Americans and native Japanese although less than that of Caucasians, but that Japanese Americans consumed fats in amounts similar to that of Caucasians, which were in fact much higher than that of native Japanese. Thus, Japanese Americans who adopted western dietary habits including higher consumption of animal fat showed higher rates of diabetes. The apparent high sensitivity of Japanese Americans to western dietary habits in terms of diabetes development required further investigation on pathophysiology of T2DM of East Asians.

Insulin Secretion and Resistance in East Asians

T2DM is characterized by insulin resistance and impaired insulin secretion. It has been proposed, based mainly on studies of Caucasian subjects, that T2DM is triggered by insulin resistance, which is compensated initially by increased β cell response, which eventually leads to T2DM due to exhaustion of pancreatic β cells [17, 18, 19]. However, as reported by our group and others, Japanese pre-diabetes and early-stage diabetes are both characterized by reduced insulin secretion along with lower insulin resistance when compared to Caucasians [20, 21, 22, 23]. These studies indicate profound differences in T2DM pathophysiology of East Asians that may be relevant for prevention and treatment of diabetes in East Asian countries.

Insulin secretory capacity has been well characterized by HOMA-β and IGI during the oral glucose tolerance test (OGTT) and, to a lesser degree, by acute insulin response during intravenous glucose tolerance test (IVGTT). Our previous studies as early as the 1970s indicated that the insulin response to ingestion of glucose in Japanese, both in normal glucose tolerance (NGT) and T2DM, was much lower than that in Caucasian [24, 25, 26, 27]. Later, cross-sectional studies in Japanese subjects with NGT, impaired glucose tolerance (IGT), and T2DM confirmed reduced insulin secretion in Japanese in comparison to those of Caucasian (Fig. 1) [20, 28]. These studies suggest that Japanese may be characterized by impaired early-phase insulin secretion, as the IGI of Japanese is lower throughout NGT via IGT to T2DM (Fig. 1), while the IGI is higher in Caucasian than in Japanese throughout all of the stages of glucose tolerance [20, 28]. Reduced insulin secretory capacity, especially in the early phase, has been reported not only in Japanese but also in other East Asians such as Korean [29, 30] and Chinese [31, 32]. Our previous investigations also suggested that the acute insulin response during IVGTT was substantially lower in Japanese compared to Caucasian [33, 34]. These findings are supported by recent important studies: (1) systematic review and meta-analysis of insulin response to glucose in IVGTT revealing reduced insulin secretory capacity of East Asians compared to Caucasians and Africans [35] and (2) studies on matched cohorts of Caucasian and Japanese subjects in OGTT and IVGTT revealing reduced β cell function in Japanese [8•, 9•]. Thus, a reduced capacity of insulin secretion is typical of East Asians, which could render them sensitive to the development of diabetes in conditions of over-nutrition.
Fig. 1

Insulin secretion and insulin resistance in Caucasian and Japanese. a Comparison of insulin response to a 75-g glucose tolerance test in Caucasian and Japanese with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and type 2 diabetes (DM). b Comparison of insulinogenic index in Caucasian and Japanese with NGT, IGT, and DM. c Comparison of homeostatic assessment insulin resistance (HOMA-IR) in Caucasian and Japanese with NGT, IGT, and DM (reproduced with permission from [10])

Insulin resistance is usually evaluated by HOMA-IR, to a lesser degree by Matsuda index or ISI composite calculated by OGTT data and less by S I, an index of insulin sensitivity derived from IVGTT data calculated by minimal model analysis. Cross-sectional studies in Japanese subjects with NGT, IGT, and T2DM demonstrated that HOMA-IR is lower in Japanese throughout NGT, IGT, and T2DM in comparison with that of Caucasian in the Botnia Study (Fig. 1) [20, 28]. In addition, Tripathy et al. reported that HOMA-IR increased approximately 2-fold as glucose tolerance deteriorated from NGT to IGT, and 3.6-fold from NGT to T2DM [28], but the change in HOMA-IR in Japanese from NGT via IGT to T2DM is not so drastic [20]. Our previous investigation using minimal model analysis during IVGTT also revealed more preserved insulin sensitivity in Japanese T2DM patients when compared indirectly to Caucasian T2DM patients [33, 34]. These findings are supported by recent studies: (1) systematic review and meta-analysis of insulin sensitivity in IVGTT finding less insulin resistance in East Asians compared to Caucasians and Africans [35] and (2) studies on matched cohorts of Caucasian and Japanese subjects revealing lower HOMA-IR and Matsuda index, but not higher S I, in Japanese throughout the different stages of glucose tolerance [8•, 9•].

Counterbalance between insulin secretion and insulin resistance is critical for T2DM pathogenesis. Being less obese with less insulin resistance, Japanese have a greater amount of visceral fats in comparison with Caucasians after adjusting for age, gender, and subcutaneous fats [36], suggesting that Japanese easily accumulate visceral fats. Thus, a subtle increase in insulin resistance due to visceral fat accumulation might well disturb the fine balance with the reduced insulin secretory capacity often seen in East Asians and easily trigger onset of type 2 diabetes. This model might well explain why there is a higher proportion of isolated IGT in isolated impaired fasting glucose (IFG), IFG/IGT, and isolated IGT in Asia than that found in Europe [37, 38]. We previously demonstrated in Japanese that the IGI is significantly reduced from NGT via isolated IGT to T2DM, while HOMA-IR is slightly but not significantly increased from isolated IGT to T2DM [39, 40]. In addition, we also demonstrated that HOMA-IR is significantly increased from NGT via isolated IFG to T2DM along with a significant reduction in IGI [40, 41]. While conversion rates from NGT to T2DM via isolated IGT, IFG/IGT, and isolated IGT need to be compared between Asians and Caucasians prospectively in the future, the model also underlie the appearance of diabetes in East Asians when not nearly as obese as Caucasian [5••, 42] as well as the increased T2DM prevalence among East Asian people such as Japanese Americans in the USA who consume similar daily energy but significantly more fats and less carbohydrates than their counterparts in Japan [43, 44]. This is consistent with the fact that diabetes is rapidly increasing in Japan and across East Asian countries today along with reduced intake of carbohydrates and increased intake of animal fats (Table 2). Future prospective studies are also needed to relate changes in dietary pattern with changes in indices related to insulin secretion and insulin resistance, along with visceral fat accumulation and adiposity-related indices including adiponectin, TNF-alpha, and newly identified progranulin [45], during the development of T2DM in East Asians.
Table 2

Changes in dietary pattern in East Asian countries and United States of America


Year of survey









Total energy intake (kcal)









 Protein (%)









 Fat (%)









 Carbohydrate (%)










Year of survey









Total energy intake (kcal)









 Protein (%)









 Fat (%)









 Carbohydrate (%)










Year of survey








Total energy intake (kcal)








 Protein (%)








 Fat (%)








 Carbohydrate (%)








United States of America

Year of survey









Total energy intake (kcal)









 Protein (%)









 Fat (%)









 Carbohydrate (%)









Data source: Japan, The National Health and Nutrition Survey, Japan and The National Nutrition Survey, Japan; China, Eur J Clin Nutr. 1993;47(5):333–46 and British Journal of Nutrition (2012), 108, 1292–1299; Korea, Malays Journal of Nutrition. 2003; 9(1):7–17 and Nutrition Research 2014; 34: 760–770; Unites States of America, U.S. Department of Agriculture, Center for Nutrition Policy and Promotion, Nutrient Content of the U.S. Food Supply. M male, F female

Unsolved Questions Regarding Low Insulin Secretory Capacity in East Asians

An important question is why East Asians show a low reserve capacity of insulin secretion. Genome-wide association study (GWAS) in Japanese found that variants in KCNQ1, the potassium voltage-gated channel subfamily Q member 1 gene, associates with T2DM [46, 47]. The KCNQ1 protein is expressed in insulin-secreting cultured cells, and the KCNQ1 blocker inhibits tolbutamide-stimulated insulin secretion, which suggests involvement of KCNQ1 in insulin secretion [48]. Following identification of variations in the KCNQ1 gene, GWAS identified in Japanese genetic variants associated with T2DM near the UBE2E2 gene and the C2CD4A/B gene [49]. The UBE2E2 gene encodes the ubiquitin-conjugating enzyme E2E2 expressed in the human pancreas and cultured insulin-secreting cells and is implicated in normal biosynthesis and secretion of insulin in pancreatic β cells [50]. The C2CD4A/B gene showed expression profiles similar to that of the UBE2E2 gene, but its protein function remains largely unknown. GWAS identified in Taiwanese T2DM-associated variants at the PTPRD and SRR loci [51] as well as the SPRY2 and CDC123 loci [52]. The PTPRD gene belongs to the receptor type IIA subfamily of protein tyrosine phosphatases, which has been implicated in neural development, cancer, and diabetes, but its function is also obscure. The SRR gene encodes a serine racemase that synthesizes d-serine from l-serine; dysregulation of d-serine could affect insulin secretion in the pathogenesis of T2DM [53, 54]. The SPRY2 and CDC123 genes encode proteins of the sprout family and the Ca2+/calmodulin-dependent protein kinase 1 subfamily, but their roles in T2DM development are unknown. More recently, studies identified several additional T2DM-susceptible genes in East Asians [55, 56], but it is difficult at this stage to know how these genes might affect β cell function in East Asians.

While many T2DM-susceptible genes found in GWAS seem related to β cell function, whether or not genetic variants in these loci might explain the reduced insulin secretory is dubious. As mentioned above, the association of westernized high fat dietary and more sedentary lifestyle habits along with the rapid increase of T2DM in East Asia suggests a thrifty gene hypothesis by which T2DM is caused by genetic variants undergoing positive selection during historical times of nutrient scarcity [57]. This hypothesis was tested for 17 confirmed T2DM-susceptible loci as well as 15 loci identified in East Asians, but no consistent selection patterns were detected [58, 59]. In addition, most of these T2DM-susceptible genes are replicated in non-East Asians, demonstrating that none of the variants itself can explain the reduced β cell function that is characteristic of East Asians. Future studies of gene-environment interactions, gene-gene interactions, and epigenetic modifications are definitely required to clarify the unique pathophysiology of East Asian diabetes.

Incretin as a Possible Link to β Cell Dysfunction in East Asians

Incretin is an important area of research related to β cell function; it has been demonstrated that incretins are responsible for more than 50–70 % of post-challenged insulin secretion in Caucasian [60, 61, 62]. The incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are secreted from the gut in response to ingestion of various nutrients including carbohydrates, proteins, and lipids, and enhance insulin secretion glucose dependently to exert their glucose-lowering effects [63, 64]. While earlier studies reported reduced GLP-1 secretion and enhanced GIP secretion in Caucasian T2DM [65, 66•, 67], later studies failed to confirm this [68•, 69•, 70], which strongly suggests that incretin secretion per se is not involved in the pathogenesis of T2DM in Caucasian. Recently, our group and others have characterized secretions of GLP-1 and GIP among NGT and T2DM and found that there are no differences among the two groups in Japanese [23, 71, 72, 73] or Korean [74, 75], indicating that incretin secretion per se is not involved in the pathogenesis of T2DM in East Asians, similar to the case in Caucasian. However, it is noteworthy that meal-induced secretion of GLP-1 is negligible in Japanese [23, 71, 76] and that the GLP-1 secretion in repose to 75-g OGTT is lower in Japanese compared to that of Caucasian when measured by the same assay system [23, 71, 77]. It remains to be determined whether the difference in GLP-1 secretion contributes to a difference in β cell function between East Asians and Caucasian.

Another difference that might contribute to ethnic variance in insulin secretory capacity could be impaired incretin action, which is a major pathophysiological characteristic of T2DM [60, 61, 62]. Attenuated GIP-induced but not GLP-1-induced insulin secretion is thought to play a role [78]. It has been shown that genetic variants of the GIP receptor have been identified as T2DM-susceptible genes by GWAS, confirming the importance of incretins in T2DM progression [79]. However, it has been demonstrated recently that the incretin effect is not impaired in Japanese and Korean T2DM subjects [75, 80]. We recently found a novel mechanism underlying glucose-dependent insulinotropic action of incretins, which is impaired in obese model rats but not in non-obese diabetic model rats [81], which is consistent with an impaired incretin effect in Caucasian and near-normal incretin effect in East Asians. As studies of incretin action on glucose-induced insulin secretion in East Asians are limited, further investigations are required to determine whether or not incretin action is involved in reduced insulin secretory capacity in East Asians.

Therapeutics for Better Prevention and Management of T2DM in East Asians

Due to reduced β cell function and lower insulin resistance, insulin secretagogues such as sulfonylureas (SU) and glinides or insulin injections have been used in the management of T2DM in Japan. In contrast to their superior effects in T2DM of Japanese and East Asians, SU and glinides are associated with hypoglycemia and body weight gain. Recently, incretin-based therapies, dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), have become widely available for management of type 2 diabetes and are used especially in East Asia. Although involvement of incretins in β cell dysfunction in East Asians is largely unknown as mentioned above, recent meta-analyses of clinical trials on DPP-4i and GLP-1RA found that the drugs are more effective in Asians [82, 83•, 84•]. Incretin-based therapies exert their glucose-lowering effects most likely by ameliorating primary β cell dysfunction through increased incretin activity [85, 86]. The greater HbA1c-lowering effects of incretin-based therapies in East Asians may confirm that β cell dysfunction has a greater responsibility for hyperglycemia in East Asians, compared with Caucasian.

Our recent studies have found a possible link between dietary habits and the efficacy of DPP-4i. The HbA1c-lowering effects of DPP-4i are enhanced by fish intake, as estimated by food records and serum levels of eicosapentaenoic acids and docosahexaenoic acids, in Japanese T2DM patients [87••, 88], presumably because nutrients in fish promote GLP-1 secretion. Indeed, we demonstrated in a cross-over setting that eating fish before rice enhanced GLP-1 secretion and ameliorated postprandial glucose excursions by increasing insulin secretion and delaying gastric emptying, in comparison with those eating fish after rice (manuscript in preparation) [89]. Similar reversal of rice and meat, which is rich in saturated and mono-unsaturated fats that enhance not only GLP-1 secretion but also that of GIP, fails to ameliorate glucose excursions may possibly facilitate fat accumulation. Indeed, small but significant body weight gain, presumably due to enhanced GIP secretion by consumption of saturated and mono-unsaturated fatty acids and increased fat deposition by GIP and these fats, is associated with deterioration of the HbA1c-lowering effects of DPP-4i in Japanese T2DM patients [90, 91]. Thus, the greater efficacy of DPP-4i in Asians may be partly due to dietary habits along with lesser insulin resistance and adiposity.

Greater glucose-lowering effects and low hypoglycemic risk of DPP-4i in Asian T2DM have made DPP-4i a widely used drug in non-obese T2DM in East Asia, especially in Japan [92, 93]; metformin serves as a first-line drug in obese T2DM in Caucasian [94, 95]. Although incretin-based therapies are thought to ameliorate β cell dysfunction with little hypoglycemia risk, cases of severe hypoglycemia were reported when DPP-4i was first introduced in Japan [96•]. The estimated incidence of hypoglycemic coma with DPP-4i sitagliptin was 16.3 per million patients during the first 6 months after its launch, approximately 6.4-fold higher in Japan than that in the USA in the corresponding period. This was partly due to the use of DPP-4i with SU, which had been widely used to improve β cell dysfunction in Japan [93]. Recent studies have detailed the mechanisms underlying severe hypoglycemia with DPP-4i and SU combinations [97, 98, 99, 100]; careful consideration to dose-titration and patient education when initiating this combination can avoid this outcome as well as improve β cell dysfunction characteristic of T2DM in East Asians.


T2DM of East Asians is characterized by β cell dysfunction rather than insulin resistance due to increased adiposity, which requires a preventative and therapeutic approach that targets β cell dysfunction precisely. While it presently remains unclear why East Asians have reduced insulin secretory capacity, lifestyle and pharmacological interventions should be rigorously investigated in the future for better prevention and management of T2DM in East Asia.



The authors thank the current and former colleagues in the field and apologize for citing only part of the relevant work due to limited space and are indebted to many authors for their contributions.

Compliance with Ethics Guidelines

Conflict of Interest

The authors declare no funding and no conflict of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    IDF Diabetes Atlas 2014 Update Sixth Edition. Brussels: International Diabetes Federation; 2014.Google Scholar
  2. 2.
    Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–40.CrossRefPubMedGoogle Scholar
  4. 4.
    Abate N, Chandalia M. The impact of ethnicity on type 2 diabetes. J Diabet Complicat. 2003;17:39–58.CrossRefGoogle Scholar
  5. 5.••
    Ntuk UE, Gill JM, Mackay DF, Sattar N, Pell JP. Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK Biobank participants. Diabetes Care. 2014;37:2500–7. An original article clarifying that East Asians develop type 2 diabetes at lower body mass index compared to Caucasians through a large multi-ethnic cohort in the UK.CrossRefPubMedGoogle Scholar
  6. 6.
    Nakanishi S, Okubo M, Yoneda M, Jitsuiki K, Yamane K, et al. A comparison between Japanese-Americans living in Hawaii and Los Angeles and native Japanese: the impact of lifestyle westernization on diabetes mellitus. Biomed Pharmacother. 2004;58:571–7.CrossRefPubMedGoogle Scholar
  7. 7.•
    Fujimoto WY, Boyko EJ, Hayashi T, Kahn SE, Leonetti DL, et al. Risk factors for type 2 diabetes: lessons learned from Japanese Americans in Seattle. J Diabetes Investig. 2012;3:212–24. An important review describing characteristics of Japanese American’s diabetes which is highly relevant to discuss pathogenesis of type 2 diabetes among East Asians.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.•
    Moller JB, Dalla Man C, Overgaard RV, Ingwersen SH, Tornoe CW, et al. Ethnic differences in insulin sensitivity, beta-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis. J Clin Endocrinol Metab. 2014;99:4273–80. An original article describing direct comparisons of insulin secretion and resistance, during intravenous glucose tolerance test, between Japanese and Caucasians.CrossRefPubMedGoogle Scholar
  9. 9.•
    Moller JB, Pedersen M, Tanaka H, Ohsugi M, Overgaard RV, et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care. 2014;37:796–804. An original article describing direct comparisons of insulin secretion and resistance, during oral glucose tolerance test, between Japanese and Caucasians.CrossRefPubMedGoogle Scholar
  10. 10.
    Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract. 2004;66S:S37–44.CrossRefGoogle Scholar
  11. 11.
    Sloan R. Ethnic distribution of diabetes mellitus in Hawaii. JAMA. 1963;183:419–24.CrossRefPubMedGoogle Scholar
  12. 12.
    Kagan A, Harris BR, Winkelstein Jr W, Johnson KG, Kato H, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. J Chron Dis. 1974;27:345–64.CrossRefPubMedGoogle Scholar
  13. 13.
    West KM. Diabetes in American Indians and other native populations of the New World. Diabetes. 1974;23:841–55.CrossRefPubMedGoogle Scholar
  14. 14.
    Olefsky JM. LIlly lecture 1980. Insulin resistance and insulin action. An in vitro and in vivo perspective. Diabetes. 1981;30:148–62.CrossRefPubMedGoogle Scholar
  15. 15.
    McNeely MJ, Boyko EJ. Type 2 diabetes prevalence in Asian Americans: results of a national health survey. Diabetes Care. 2004;27:66–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Fujimoto WY, Hershon K, Kinyoun J, Stolov W, Weinberg C, et al. Type II diabetes mellitus in Seattle and Tokyo. Tohoku J Exp Med. 1983;141(Suppl):133–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2005;54:166–74.CrossRefPubMedGoogle Scholar
  18. 18.
    Ogihara T, Mirmira RG. An islet in distress: beta cell failure in type 2 diabetes. J Diabetes Investig. 2010;1:123–33.PubMedCentralPubMedGoogle Scholar
  19. 19.
    DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88:787–835. ix.CrossRefPubMedGoogle Scholar
  20. 20.
    Fukushima M, Usami M, Ikeda M, Nakai Y, Taniguchi A, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism. 2004;53:831–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia. 1984;26:44–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Iwahashi H, Okauchi Y, Ryo M, Noguchi M, Morita S, et al. Insulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patients. J Diabetes Investig. 2012;3:271–5.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Yabe D, Kuroe A, Watanabe K, Iwasaki M, Hamasaki A, et al. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. J Diabet Complicat. 2015;29(3):413–21.Google Scholar
  24. 24.
    Seino Y, Taminato T, Goto Y, Ikeda M, Imura H. Comparative insulinogenic effect of glucose, arginine and glucagon in patients with diabetes mellitus, endocrine disorders and liver disease. Acta Diabetol. 1975;12(2):89–99.CrossRefGoogle Scholar
  25. 25.
    Kosaka K, Kuzuya T, Akanuma Y, Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia. 1980;18:23–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Seino Y, Goto Y, Kurahachi H, Sakurai H, Ikeda M. Alteration of plasma glucagon response to arginine after treatment in patients with diabetes mellitus, Cushing’s syndrome and hypothyroidism. Horm Metab Res. 1977;9:28–32.CrossRefPubMedGoogle Scholar
  27. 27.
    Seino Y, Ikeda M, Kurahachi H, Taminato T, Sakurai H, et al. Failure of suppress plasma glucagon concentrations by orally administered glucose in diabetic patients after treatment. Diabetes. 1978;27:1145–50.CrossRefPubMedGoogle Scholar
  28. 28.
    Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes. 2000;49:975–80.CrossRefPubMedGoogle Scholar
  29. 29.
    Kim DJ, Lee MS, Kim KW, Lee MK. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism. 2001;50:590–3.CrossRefPubMedGoogle Scholar
  30. 30.
    Choi YH, Ahn YB, Yoon KH, Kang MI, Cha BY, et al. New ADA criteria in the Korean population: fasting blood glucose is not enough for diagnosis of mild diabetes especially in the elderly. Korean J Intern Med. 2000;15:211–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Qian L, Xu L, Wang X, Fu X, Gu Y, et al. Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation. Diabetes Metab Res Rev. 2009;25:144–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Pang C, Bao YQ, Wang C, Lu JX, Jia WP, et al. Relationship between the level of fasting plasma glucose and beta cell functions in Chinese with or without diabetes. Chin Med J (Engl). 2008;121:2119–23.Google Scholar
  33. 33.
    Taniguchi A, Nakai Y, Fukushima M, Kawamura H, Imura H, et al. Pathogenic factors responsible for glucose intolerance in patients with NIDDM. Diabetes. 1992;41:1540–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Welch S, Gebhart SS, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab. 1990;71:1508–18.CrossRefPubMedGoogle Scholar
  35. 35.
    Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, et al. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care. 2013;36:1789–96.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Tanaka S, Horimai C, Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis. Acta Diabetol. 2003;40 Suppl 1:S302–4.CrossRefPubMedGoogle Scholar
  37. 37.
    DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 1998;317:371–75.Google Scholar
  38. 38.
    Qiao Q, Nakagami T, Tuomilehto J, Borch-Johnsen K, Balkau B, et al. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia. 2000;43:1470–5.CrossRefPubMedGoogle Scholar
  39. 39.
    Suzuki H, Fukushima M, Usami M, Ikeda M, Taniguchi A, et al. Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes Care. 2003;26:1211–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Mitsui R, Fukushima M, Taniguchi A, Nakai Y, Aoyama S, et al. Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese. J Diabetes Investig. 2012;3:377–83.CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Nishi Y, Fukushima M, Suzuki H, Mitsui R, Ueda N, et al. Insulin secretion and insulin sensitivity in Japanese subjects with impaired fasting glucose and isolated fasting hyperglycemia. Diabetes Res Clin Pract. 2005;70:46–52.CrossRefPubMedGoogle Scholar
  42. 42.
    Nakagami T, Qiao Q, Carstensen B, Nhr-Hansen C, Hu G, et al. Age, body mass index and type 2 diabetes-associations modified by ethnicity. Diabetologia. 2003;46:1063–70.CrossRefPubMedGoogle Scholar
  43. 43.
    Fujimoto WY, Leonetti DL, Kinyoun JL, Shuman WP, Stolov WC, et al. Prevalence of complications among second-generation Japanese-American men with diabetes, impaired glucose tolerance, or normal glucose tolerance. Diabetes. 1987;36:730–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Fujimoto WY, Leonetti DL, Kinyoun JL, Newell-Morris L, Shuman WP, et al. Prevalence of diabetes mellitus and impaired glucose tolerance among second-generation Japanese-American men. Diabetes. 1987;36:721–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Matsubara T, Mita A, Minami K, Hosooka T, Kitazawa S, et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab. 2012;15:38–50.CrossRefPubMedGoogle Scholar
  46. 46.
    Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet. 2008;40:1092–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet. 2008;40:1098–102.CrossRefPubMedGoogle Scholar
  48. 48.
    Ullrich S, Su J, Ranta F, Wittekindt OH, Ris F, et al. Effects of I(Ks) channel inhibitors in insulin-secreting INS-1 cells. Pflugers Arch. 2005;451:428–36.CrossRefPubMedGoogle Scholar
  49. 49.
    Yamauchi T, Hara K, Maeda S, Yasuda K, Takahashi A, et al. A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat Genet. 2010;42:864–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Kimura M, Hattori T, Matsuda Y, Yoshioka T, Sumi N, et al. cDNA cloning, characterization, and chromosome mapping of UBE2E2 encoding a human ubiquitin-conjugating E2 enzyme. Cytogenet Cell Genet. 1997;78:107–11.CrossRefPubMedGoogle Scholar
  51. 51.
    Tsai FJ, Yang CF, Chen CC, Chuang LM, Lu CH, et al. A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genet. 2010;6:e1000847.CrossRefPubMedCentralPubMedGoogle Scholar
  52. 52.
    Shu XO, Long J, Cai Q, Qi L, Xiang YB, et al. Identification of new genetic risk variants for type 2 diabetes. PLoS Genet. 2010;6:e1001127.CrossRefPubMedCentralPubMedGoogle Scholar
  53. 53.
    Wolosker H, Blackshaw S, Snyder SH. Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci U S A. 1999;96:13409–14.CrossRefPubMedCentralPubMedGoogle Scholar
  54. 54.
    Gonoi T, Mizuno N, Inagaki N, Kuromi H, Seino Y, et al. Functional neuronal ionotropic glutamate receptors are expressed in the non-neuronal cell line MIN6. J Biol Chem. 1994;269:16989–92.PubMedGoogle Scholar
  55. 55.
    Cho YS, Chen CH, Hu C, Long J, Ong RT, et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in East Asians. Nat Genet. 2012;44:67–72.CrossRefGoogle Scholar
  56. 56.
    Hwang JY, Sim X, Wu Y, Liang J, Tabara Y, et al. Genome-wide association meta-analysis identifies novel variants associated with fasting plasma glucose in East Asians. Diabetes. 2015;64(1):291–8.Google Scholar
  57. 57.
    Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet. 1962;14:353–62.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Southam L, Soranzo N, Montgomery SB, Frayling TM, McCarthy MI, et al. Is the thrifty genotype hypothesis supported by evidence based on confirmed type 2 diabetes- and obesity-susceptibility variants? Diabetologia. 2009;52:1846–51.CrossRefPubMedCentralPubMedGoogle Scholar
  59. 59.
    Cho YS, Lee JY, Park KS, Nho CW. Genetics of type 2 diabetes in East Asian populations. Curr Diabetes Rep. 2012;12:686–96.CrossRefGoogle Scholar
  60. 60.
    Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63:492–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56:1951–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, et al. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:737–45.CrossRefPubMedGoogle Scholar
  63. 63.
    Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1:9–23.Google Scholar
  64. 64.
    Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation. Prog Biophys Mol Biol. 2011;107:248–56.CrossRefPubMedGoogle Scholar
  65. 65.
    Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.CrossRefPubMedGoogle Scholar
  66. 66.•
    Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013;62:3316–23. A useful review of intra- and extrapancreatic actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1, which is highly relevant to discuss efficacy and safety of incretin-based therapies in the management of type 2 diabetes.CrossRefPubMedCentralPubMedGoogle Scholar
  67. 67.
    Seino Y, Yabe D. GIP and GLP-1: incretin actions beyond pancreas. J Diabetes Investig. 2013;4:108–30.CrossRefPubMedCentralPubMedGoogle Scholar
  68. 68.•
    Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56:965–72. An important systematic review and meta-analysis comparing secretion of glucagon-like peptide-1 between subjects with type 2 diabetes and normal glucose-tolerance.CrossRefPubMedCentralPubMedGoogle Scholar
  69. 69.•
    Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, et al. Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care. 2013;36:3346–52. An important systematic review and meta-analysis comparing secretion of glucose-dependent insulinotropic polypeptide between subjects with type 2 diabetes and normal glucose-tolerance.CrossRefPubMedCentralPubMedGoogle Scholar
  70. 70.
    Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54(1):10–8.Google Scholar
  71. 71.
    Yabe D, Kuroe A, Lee S, Watanabe K, Hyo T, et al. Little enhancement of meal-induced GLP-1 secretion in Japanese: comparison of type 2 diabetes and healthy controls. J Diabetes Investig. 2010;1:56–9.CrossRefPubMedCentralPubMedGoogle Scholar
  72. 72.
    Kozawa J, Okita K, Imagawa A, Iwahashi H, Holst JJ, et al. Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. Biochem Biophys Res Commun. 2010;393:410–3.CrossRefPubMedGoogle Scholar
  73. 73.
    Lee S, Yabe D, Nohtomi K, Takada M, Morita R, et al. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J. 2010;57:119–26.CrossRefPubMedGoogle Scholar
  74. 74.
    Oh TJ, Park KS, Cho YM. Correlation of the incretin effect with first- and second-phase insulin secretions in Koreans with various glucose tolerance statuses. Clin Endocrinol (Oxf). 2014. doi: 10.1111/cen.12623.
  75. 75.
    Oh TJ, Kim MY, Shin JY, Lee JC, Kim S, et al. The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes. Clin Endocrinol (Oxf). 2014;80:221–7.CrossRefGoogle Scholar
  76. 76.
    Yabe D, Watanabe K, Sugawara K, Kuwata H, Kitamoto Y, et al. Comparison of incretin immunoassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012;3:70–9.CrossRefPubMedCentralPubMedGoogle Scholar
  77. 77.
    Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008;57:678–87.CrossRefPubMedGoogle Scholar
  78. 78.
    Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 2002;45:1111–9.CrossRefPubMedGoogle Scholar
  79. 79.
    Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet. 2010;42:142–8.CrossRefPubMedCentralPubMedGoogle Scholar
  80. 80.
    Hamasaki A, Harada N, Muraoka A, Yamane S, Joo E, et al. Not glucose tolerance but obesity impairs the numerical incretin effect in Japanese subjects. Diabetologia. 2011;54:S217.Google Scholar
  81. 81.
    Gheni G, Ogura M, Iwasaki M, Yokoi N, Minami K, et al. Glutamate acts as a key signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion. Cell Rep. 2014;9:661–73.CrossRefPubMedGoogle Scholar
  82. 82.
    Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012;46:1453–69.CrossRefPubMedGoogle Scholar
  83. 83.•
    Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and Non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696–708. An important systematic review and meta-analysis comparing glucose-lowering effects of dipeptidyl-peptidase-4 inhibitors between Asians and non-Asians.CrossRefPubMedGoogle Scholar
  84. 84.•
    Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(10):900–9.An important systematic review and meta-analysis comparing glucose-lowering effects of glucagon-like peptide-1 between Asians and non-Asians. Google Scholar
  85. 85.
    Kubota A, Matsuba I, Saito T, Nabe K, Seino Y. Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus. J Diabetes Investig. 2011;2:377–80.CrossRefPubMedCentralPubMedGoogle Scholar
  86. 86.
    Seino Y, Rasmussen MF, Clauson P, Kaku K. The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012;3:388–95.CrossRefPubMedCentralPubMedGoogle Scholar
  87. 87.••
    Iwasaki M, Hoshian F, Tsuji T, Hirose N, Matsumoto T, et al. Predicting efficacy of DPP-4 inhibitors in patients with type 2 diabetes: association of HbA1c reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Investig. 2012;3:464–7. An original article identifying a novel interaction of dietary habits and HbA1c-lowering of dipeptidyl-peptidase-4 inhibitors.CrossRefPubMedCentralPubMedGoogle Scholar
  88. 88.
    Senmaru T, Fukui M, Kobayashi K, Iwase H, Inada S, et al. Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. J Diabetes Investig. 2012;3:498–502.CrossRefPubMedCentralPubMedGoogle Scholar
  89. 89.
    Yabe D, Kuwata H, Iwasaki M, Usui R, Kurose T, et al. Effects of fish or meat intake before and after rice on postprandial glucose excursions and incretin secretion in type 2 diabetes: meal sequence as a novel target in dietary therapies for diabetes. Diabetes. 2014;64:LB12.Google Scholar
  90. 90.
    Kubota A, Yabe D, Kanamori A, Kuroe A, Takahashi N, et al. Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea. J Diabetes Investig. 2014;5:445–8.CrossRefPubMedCentralPubMedGoogle Scholar
  91. 91.
    Kanamori A, Matsuba I. Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer. J Clin Med Res. 2013;5:217–21.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Yabe D, Kuwata H, Kaneko M, Ito C, Nishikino R, et al. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. Diabetes Obes Metab. 2015;17(4):430–34.Google Scholar
  93. 93.
    Kohro T, Yamazaki T, Sato H, Harada K, Ohe K, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J. 2013;54:93–7.CrossRefPubMedGoogle Scholar
  94. 94.
    Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.CrossRefPubMedGoogle Scholar
  95. 95.
    Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.CrossRefPubMedCentralPubMedGoogle Scholar
  96. 96.•
    Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabetes Investig. 2014;5:475–7. An article comparing incidence of severe hypoglycemia by dipeptidyl peptidase-4 inhibitors in Japan and the USA.CrossRefPubMedCentralPubMedGoogle Scholar
  97. 97.
    Takahashi H, Shibasaki T, Park JH, Hidaka S, Takahashi T, et al. Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion. Diabetes. 2015;64(4):1262–72.Google Scholar
  98. 98.
    Shibasaki T, Takahashi T, Takahashi H, Seino S. Cooperation between cAMP signalling and sulfonylurea in insulin secretion. Diabetes Obes Metab. 2014;16 Suppl 1:118–25.CrossRefPubMedGoogle Scholar
  99. 99.
    Takahashi T, Shibasaki T, Takahashi H, Sugawara K, Ono A, et al. Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. Sci Signal. 2013;6:ra94.PubMedGoogle Scholar
  100. 100.
    Mukai E, Fujimoto S, Sato H, Oneyama C, Kominato R, et al. Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes. 2010;60:218–26.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Daisuke Yabe
    • 1
    • 2
    • 3
    Email author
  • Yutaka Seino
    • 1
  • Mitsuo Fukushima
    • 1
    • 3
    • 4
  • Susumu Seino
    • 3
  1. 1.Center for Diabetes, Endocrinology and MetabolismKansai Electric Power HospitalOsakaJapan
  2. 2.Center for Metabolism and Clinical NutritionKansai Electric Power HospitalOsakaJapan
  3. 3.Division of Molecular and Metabolic MedicineKobe University Graduate School of MedicineKobeJapan
  4. 4.Department of Nutritional ScienceOkayama Prefectural UniversityOkayamaJapan

Personalised recommendations